VeraMorph lands $2.1M NIH grant, taps ex-Eagle executive as CEO
What's the deal? VeraMorphDealroom has a profile for this one. Try Dealroom →, a specialty pharmaceutical startup, has received a $2.1 million SBIR Phase II grant from the National Institutes of HealthDealroom has a profile for this one. Try Dealroom → to fund IND-enabling work on its oral formulation of fulvestrant, a breast cancer therapy. It also named Daniel O'Connor as chief executive officer.
What's the endgame? The company uses a "degradable gel" oral drug delivery platform to reformulate existing drugs. Its lead product aims to turn fulvestrant — now given by monthly injection — into a pill for patients with estrogen receptor positive metastatic breast cancer.
Why now? The grant follows a pre-IND meeting in which the Food and Drug Administration signalled openness to VeraMorph's clinical strategy, which starts with studies in healthy volunteers. The funds will complete remaining preclinical studies, with the company targeting a clinical entry in 2027 and an NDA filing in 2029.
The hire: O'Connor is the former chief strategy officer of Eagle Pharmaceuticals, where he led the NDA filing for a novel injectable fulvestrant. Founder Doug Godfrin moves to president and chief technology officer. "The long history of fulvestrant provides confidence in the potential for a superior therapy among this patient population," O'Connor said.
By the numbers: VeraMorph says preclinical results showed 20 times higher maximum plasma concentrations than the injectable product without severe adverse events. It is targeting the roughly 70% of ER+ metastatic breast cancer patients who retain a wild-type ESR1 gene, within an oral SERD market the company estimates at $3 billion to $6 billion.
What could go wrong? The grant is non-dilutive support for preclinical work, not a clinical-stage financing — VeraMorph says it is still raising a seed round for first-in-human studies. Encouraging animal-model data and FDA feedback do not establish human safety or efficacy, and the 2029 NDA target is distant.
The signal: VeraMorph enters a crowded field, with oral SERDs from Roche and AstraZeneca advancing in late-stage trials. Unlike those mutation-defined rivals, fulvestrant's efficacy is independent of ESR1 status — but for now, the grant and CEO appointment are early development milestones, not commercial validation.
Read more: lifestyle.gopreneurs.com
Image credit: Veramorph
